Long-Term Use of Recombinant Human Growth Hormone (rhGH) in Children with Chronic Renal Insufficiency (CRI)

Fine, Richard Ν.

doi:10.1297/cpe.6.supple10_81

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RhGH could improve HV in both predialysis and dialsyis patients but it turned out that the improvement in HV was significantly poorer in the dialysis group than in the predialysis children on the same dose of rhGH . The beneficial effect of short term rhGH treatment in growth retarded children with CRF has already been reported by other authors and our present study confirmed their results (5)(6)(7)(8)(9)(10)(11)(12)(13). We observed negative side effects of rhGH, but in only a small number of children.…”

Section: Disussionsupporting

confidence: 93%

The Use of Recombinant Human GH (rhGH) in Growth Failure in Children with Various Renal Diseases

Ito

Kawaguchi

1997

Clin Pediatr Endocrinol

View full text Add to dashboard Cite

We evaluated the 1 year effect of recombinant human GH (rhGH), of 0.5 or 1.0 IU/kg/week, on growth in 83 cases of chronic renal failure (CRF) (pre and dialysis), 23 transplanted and 18 children with nephrotic syndrome. In predialysis children height growth velocity (HV) became to be significantly increased from 3.8 at baseline to 7.8 at 6 months and 7.3 cm/year at 1 year with a dose of 0.5 IU (p<0.001). When treated with 1.0 IU, HV was increased from 4.5 to 10.3 at 6 and 8.7 cm/yaer at 1 year (P<0.001). When a comparison was done for the increase in HV, a significant difference was noted between 0.5 IU and 1.0 IU at both 6 and 12 months (P<0.01). In dialyzed children treated with 0.5 IU, HV was significantly increased from 3.5 to 5.6 at 6 months (P<0.01) and 5.4 cm/year at 1 year (P<0.01). In the 1.0 IU group, it was from 3.4 to 8.4 at 6 months (P<0.001) and 8.3 cm/year at 1 year (P<0.01). There was a significant difference in HV between 0.5 and 1.0 IU at both 6 and 12 months (P<0.01). In transplanted children, HV was significantly improved from 5.0 to 7.7 cm/year with 0.5 IU (P<0.05) and from 3.7 to 6.3 cm/year with 1.0 IU (P<0.05) during 1 year of GH treatment but there was no statistical difference between the two groups. Seven out of 23 children showed deterioration of graft function during rhGH treatment due to acute rejection (AR) in all cases. AR was noted in 2 out of 10 children (20%) in the 0.5 IU and 5 out of 13 children (38%) in the 1.0 IU group. In nephrtotic syndrome, HV was increased from 3.3 to 6.5 cm/year at 1 year and to 6.4 cm/year at 2 year (P<0.05). Our results demonstrated that rhGH is effective to stimulating HV in not only CRF but also transplants and nephrotic syndome.

show abstract